Bolus Insulin Card Calculator Randomised Controlled Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by John Hunter Children's Hospital.
Recruitment status was  Recruiting
Royal North Shore Hospital
Sydney Children's Hospital, Randwick
Royal Children's Hospital
Mater Children's Hospital
NovoNordisk Pharmaceuticals
Information provided by:
John Hunter Children's Hospital Identifier:
First received: September 5, 2008
Last updated: February 5, 2010
Last verified: August 2009
In pediatric patients with type 1 diabetes using subcutaneous injections; a randomised controlled trial comparing the effects of fixed carbohydrate exchanges and insulin doses to the use of variable size meals and insulin doses determined with a bolus insulin calculation card.

Condition Intervention
Type 1 Diabetes
Device: ezy-BICC dose calculation card
Other: Fixed dose

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bolus Insulin Card Calculator Randomised Controlled Study

Resource links provided by NLM:

Further study details as provided by John Hunter Children's Hospital:

Primary Outcome Measures:
  • 24 hours BGL > 8.3mmol/l (CGMS) [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HbA1c [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: March 2008
Estimated Study Completion Date: January 2011
Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fixed dose
Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
Other: Fixed dose
Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
Experimental: ezy-BICC dose calculation card
variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
Device: ezy-BICC dose calculation card
small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject


Ages Eligible for Study:   11 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 11 - 18 years old
  • Currently using indvidual subcutaneous injections (not CSII)

Exclusion Criteria:

  • HbA1c > 9.5%
  • Serious illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00748137

Contact: Donald Anderson, FRACP 61-2-49855634
Contact: Elizabeth Nunn, BSc 61-2-49855634

Australia, New South Wales
Gosford District Hospital Recruiting
Gosford, New South Wales, Australia, 2915
Principal Investigator: Monique Stone, MD         
John Hunter Children's Hospital Recruiting
Newcastle, New South Wales, Australia, 2305
Contact: Donald Anderson, MBBS FRACP    +61 2 49855634   
Contact: Liz Nunn, BHSc    61 2 49213753   
Principal Investigator: Donald G Anderson, MBBS FRACP Grad Dip Biostat         
Sub-Investigator: Elizabeth Nunn, BHSc Grad Dip Epid         
Sub-Investigator: Dierdre Burgess, BSc         
Sydney Children's Hospital Recruiting
Sydney, New South Wales, Australia
Principal Investigator: Charles Verge, MD         
Australia, Queensland
Mater Children's Hospital Recruiting
Brisbane, Queensland, Australia
Principal Investigator: Mark Harris, MD         
Sub-Investigator: Bridgid Knight         
Royal Children's Hospital Recruiting
Brisbane, Queensland, Australia
Principal Investigator: Sarah MacMahon, MD         
Sponsors and Collaborators
John Hunter Children's Hospital
Royal North Shore Hospital
Sydney Children's Hospital, Randwick
Royal Children's Hospital
Mater Children's Hospital
NovoNordisk Pharmaceuticals
  More Information

No publications provided

Responsible Party: Dr Donald Anderson, Staff Specialist, John HUnter Children's Hospital Identifier: NCT00748137     History of Changes
Other Study ID Numbers: 06/04/26/5.01 
Study First Received: September 5, 2008
Last Updated: February 5, 2010
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by John Hunter Children's Hospital:
Type 1 Diabetes
Insulin dose

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Autoimmune Diseases
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on February 04, 2016